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ABSTRACT
Background. Chronic kidney disease–mineral and bone dis-
orders (CKD–MBD) are important complications of CKD5D
patients that are associated with mortality.
Methods. COSMOS is a multicentre, open cohort, prospective,
observational 3-year study carried out in haemodialysis
patients from 20 European countries during 2005–07. The
present article describes the main characteristics of the Euro-
pean dialysis population, the current practice for the preven-
tion, diagnosis and treatment of secondary
hyperparathyroidism and the differences across different
European regions.
Results. The haemodialysis population in Europe is an aged
population (mean age 64.8 ± 14.2 years) with a high preva-
lence of diabetes (29.5%) and cardiovascular disease (76.0%),
and 28.7% of patients have been on haemodialysis more than
5 years. Patients from the former Eastern countries are
younger (59.3 ± 14.3 versus 66.0 ± 13.9), having a lower pro-
portion of diabetics (24.1 versus 30.7%). There were relevant
differences in the frequency of measurement of the main
CKD–MBD biochemical parameters [Ca, P and parathyroid
hormone (PTH)] and the Eastern countries showed a poorer
control of these biochemical parameters (K/DOQI and K/
DIGO targets). Overall, 48.0% of the haemodialysis patients
received active vitamin D treatment. Calcitriol use doubled
that of alfacalcidiol in the Mediterranean countries, whereas
the opposite was found in the non-Mediterranean countries.
The criteria followed to perform parathyroidectomy were
different across Europe. In the Mediterranean countries, the
level of serum PTH considered to perform parathyroidectomy
was higher than in non-Mediterranean countries; as a result,
in the latter, more parathyroidectomies were performed in the
year previous to inclusion to COSMOS.
Conclusions. The COSMOS baseline results show important
differences across Europe in the management of CKD–MBD.
INTRODUCTION
Chronic kidney disease–mineral and bone disorders (CKD-
MBD) are current complications of CKD patients with end-
stage renal disease (CKD5D). Despite the great advances in
the knowledge of the pathogenesis of these disorders and the
availability of new drugs, the control of CKD–MBD is still
inadequate and it has been associated with increased morbid-
ity and mortality [1–5].
In order to improve CKD–MBD outcomes, in 2003, the
National Kidney Foundation launched the Kidney Dialysis
Outcome Initiative (K/DOQI) [6], some years later, in 2009,
the Kidney Disease: Improving Global Outcomes (K/DIGO)
initiative launched new CKD–MBD guidelines [7].
Since the publication of the K/DOQI guidelines, several ret-
rospective and prospective epidemiological studies have been
carried out in order to better identify the main factors impli-
cated in CKD–MBD outcomes [8–14]. COSMOS (Current
Management of Secondary hyperparathyroidism—a Multicen-
ter Observational Study) is a Pan-European prospective study
which aims to survey MBD and clinical practice patterns in
CKD5D patients [15, 16]. The main objective of COSMOS is
to survey bone mineral disturbances in the haemodialysis
population in Europe and current practice for the prevention,
diagnosis and treatment of secondary hyperparathyroidism. In
the present report, the most relevant baseline clinical, bio-
chemical and practice patterns in Europe are presented.
MATERIALS AND METHODS
COSMOS is a 3-year, multicentre, open-cohort, prospective
observational study surveying bone and mineral disturbances
in 20 European countries including 4500 prevalent CKD5
patients older than 18 years from 227 dialysis centres. Facilities
were identiﬁed using a stratiﬁed, random selection method-
ology and 20 patients from each haemodialysis facility were
randomly recruited. The number of patients per country was
proportional to the haemodialysis population of each country.
The larger countries were divided into three to ﬁve geographic
areas, and haemodialysis sites were randomly selected within
those predeﬁned areas. Germany was divided into four regions
(north, south, west and east), Italy and France into three
regions (north, centre and south), Spain into three regions
(north, south and east) and Poland into ﬁve regions (north,
south, east, west and centre). The detailed study protocol
design has been published elsewhere [15]. Only haemodialysis
centres with more than 40 patients were included.
Centre and patient data were entered by site investigators
into a web-based data entry system. Recruitment of sites and
patients began in February 2005 and ﬁnished in July 2007.
Data were collected in two web-based-speciﬁc forms (Table 1).
Each centre completed a centre-speciﬁc form with 15 ques-
tions and 119 items including site characteristics and practice
patterns and a patient form with 27 questions and 185 items
[15] (Supplementary material, Table S1A and B). The patient
data included laboratory parameters from the previous 6
months before inclusion. The mean values for these 6 months
were calculated for each patient. The serum parathyroid
hormone (PTH) assay used was recorded in the majority of
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centres (79.3%). In the corrections of PTH values, the Elecsys
PTH (Roche Diagnostics) was used as a comparator due to its
better performance [17] and also because it was the assay
more often used in COSMOS (42% of the reported assays).
PTH levels from sites measuring bio-intact assay (3.5%, 8
centres) were corrected multiplying by 1.95, as it has been pre-
viously described [18, 19]. Each investigator received a user-
name and password and data could only be introduced or
modiﬁed by the investigator. In order to prevent typographical
mistakes, the values introduced in quantitative variables were
contrasted with predetermined ranges; otherwise, the investi-
gator was required to correct the introduced value.
The analysis of data (centre and patient forms) was done
for the whole COSMOS population. In addition, a further
analysis was performed grouping European regions according
to economic, historical and sociocultural similarities. The
countries were divided into Eastern (Croatia, Czech Republic,
Hungary, Poland, Romania and Slovenia) and Western Euro-
pean countries (Austria, Belgium, Denmark, Finland, France,
Germany, Greece, Italy, the Netherlands, Portugal, Spain,
Table 1. Variables collected from each site (centre-speciﬁc form) and from each patient (patient
form)
Centre-speciﬁc form Patient form
1. Site characteristics (type and funding) 1. Year of birth
2. Centre size (number of patients) 2. Gender
3. Frequency of bone x-ray proﬁle 3. Prescribed dry weight
4. Type of x-ray 4. Height
5. Timing of laboratory data collection 5. Aetiology of CKD
6. Frequency of PTH measurement 6. Year of initiation dialysis
7. Frequency of Ca and P measurement 7. Type of haemodialysis treatment
8. Use of a standard dialysate calcium 8. Haemodialysis hours per week
9. Type of PTH assay used 9. Comorbidity of diabetes
10. Level of PTH considered to initiate treatment 10. Bone biopsy (diagnosis)
11. Route and frequency of vitamin D analogues/metabolites
administration
11. Presence of symptomatic bone fractures in previous 1
year
12. Level of PTH considered for parathyroidectomy 12. Presence and year of parathyroidectomy
13. Type of parathyroidectomy 13. Cardiovascular disease events
14. Number of parathyroidectomies performed in the last year 14. Cigarette smoking
15. Clinical guidelines followed 15. Presence of calciﬁcations, technique used for detection
and location
16. Calcium concentration in dialysate
17. Phosphate binder usage
18. Nutritional vitamin D usage
19. Vitamin D metabolites/analogues usage
20. Calcimimetics usage
21. Erythropoietic-stimulating agents usage
22. Serum parathyroid hormone (previous 6 months)
23. Serum phosphate (previous 6 months)
24. Serum calcium (previous 6 months)
25. Serum albumin (previous 6 months)
26. Haemoglobin level (previous 6 months)
27. Serum aluminium (previous 6 months)
Ca, calcium; P, phosphorous; PTH, parathyroid hormone; CKD, chronic kidney disease.
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Sweden, Switzerland and UK). Additionally, a second geo-
graphical analysis divided Europe into Mediterranean
(Croatia, France, Greece, Italy, Portugal, Slovenia and Spain)
and non-Mediterranean countries (Austria, Belgium, Czech
Republic, Denmark, Finland, Germany, Hungary, the Nether-
lands, Poland, Romania, Sweden, Switzerland and UK).
Categorical variables were described as the percentage of
patients and quantitative variables as the mean and standard
deviation. One-way analysis of variance (ANOVA) test for
continuous variables and the χ2 test for categorical variables
were used to analyse differences between European regions
using the Statistical Analysis Software SAS® (version 9.2). The
Cochran–Mantel–Haenszel test was also used for categorical
variables to adjust by age and gender when comparing the
different European regions.
RESULTS
Seventeen out of the 20 included countries recruited more
than 80% of the targeted population—14 of them reached
93.9% or higher, two others more than 50% (Germany and
Italy) and one country recruited 24% (UK). Overall, 76.8% of
the targeted population was recruited (Table 2).
Most of the dialysis centres participating in COSMOS were
hospital-based (67.8%), non-academic (73.3%) and publicly
funded (64.6%). (For a full list of centres participating in the
COSMOS study, please see the supplementary material
online). In Eastern Europe and Mediterranean countries, the
percentage of hospital-based dialysis centres was signiﬁcantly
higher than in Western Europe and non-Mediterranean
countries, respectively. No statistically signiﬁcant differences
between public or private funding were observed across
regions (Table 3).
Almost 60% of the dialysis patients included were men and
were older than 65 years (overall mean age 64.8 ± 14.2 years)
(Table 3). In Western countries, the percentage of patients
older than 65 years was higher (mean age 66.0 ± 13.9 years),
almost 7 years older on average than in the Eastern countries.
The Mediterranean patients were also older (3 years) than the
non-Mediterranean patients. Small, but signiﬁcant, differences
in body mass index and smoking habits were observed
Table 2. Facilities and patients targeted and achieved for recruitment in number (n) and
percentages (%)
Country Targeted Achieved Achieved/targeted
Facilities (n) Patients (n) Facilities (n) Patients (n) Facilities (%) Patients (%)
Austria 5 100 5 98 100.0 98.0
Belgium 7 140 6 120 85.7 85.7
Croatia 3 60 3 62 100.0 103.3
Czech Republic 7 140 7 140 100.0 100.0
Denmark 3 60 3 58 100.0 96.7
Finland 2 40 2 39 100.0 97.5
France 38 760 32 633 84.2 83.3
Germany 73 1460 51 1018 69.9 69.7
Greece 10 200 10 199 100.0 99.5
Hungary 6 120 6 120 100.0 100.0
Italy 50 1000 28 554 56.0 55.4
The Netherlands 6 120 6 119 100.0 99.2
Poland 15 300 15 302 100.0 100.7
Portugal 10 200 11 203 110.0 101.5
Romania 7 140 7 140 100.0 100.0
Slovenia 2 40 2 46 100.0 115.0
Spain 22 440 21 413 95.5 93.9
Sweden 4 80 4 80 100.0 100.0
Switzerland 3 60 3 60 100.0 100.0
UK 20 400 5 96 25.0 24.0
Total 293 5860 227 4500 77.5 76.8
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Table 3. Characteristics of sites and patients
Facilities All
(n = 227)
East
(n = 40)
West
(n = 187)
P-value Medit.
(n = 107)
Non-Medit.
(n = 120)
P-value
Type of centre
Hospital-based (%) 67.8 92.5 62.6 <0.001 74.8 61.7 0.035
Non-academic (%) 73.3 79.5 72.0 0.3 71.7 74.8 0.6
Public (%) 64.6 75.0 62.4 0.1 64.2 65.0 0.9
Patients n = 4500 n = 810 n = 3690 n = 2110 n = 2390
Age (years)
(Mean ± SD)
64.8 ± 14.2 59.3 ± 14.3 66.0 ± 13.9 <0.001 66.4 ± 13.8 63.4 ± 14.4 <0.001
≥65 (%) 58.1 40.0 62.1 <0.001 63.5 53.4 <0.001
Gender (males) (%) 59.7 55.7 60.5 0.011 60.2 59.2 0.3
Body mass index (kg/
m²) (mean ± SD)
25.5 ± 10.3 25.2 ± 5.2 25.3 ± 5.0 0.6 24.9 ± 4.8 25.6 ± 5.2 <0.001
<20.0 (%) 11.2 12.7 10.8 0.2 12.5 10.0 <0.001
20.0–<25.0 (%) 43.0 41.5 43.4 44.6 41.6
25.0–<30 (%) 30.4 31.7 30.2 29.5 31.3
≥30.0 (%) 15.4 14.1 15.7 13.4 17.1
Smokers (%) 14.2 14.8 14.0 0.1 12.7 15.4 0.5
Years on
haemodialysis
4.2 ± 4.4 3.8 ± 4.0 4.2 ± 4.5 0.014 4.7 ± 5.0 3.7 ± 3.8 <0.001
<1 (%) 18.7 19.6 18.5 0.1 17.1 20.1 <0.001
1–5 (%) 52.7 54.6 52.2 50.4 54.7
>5 (%) 28.7 25.8 29.3 32.6 25.2
Primary aetiology of CKD
Diabetic
nephropathy (%)
20.4 16.5 21.3 <0.001 17.7 22.8 <0.001
Hypertensiona (%) 19.3 14.8 20.3 20.8 18.0
Glomerulonephritis
(%)
17.8 21.5 17.0 17.3 18.3
Inters/obs
nephropathyb
(%)
12.8 20.9 11.1 12.7 12.9
Unknown (%) 11.3 7.7 12.1 15.0 8.0
PKD (%) 8.7 10.0 8.5 8.7 8.7
Tumours (%) 1.6 1.1 1.7 1.7 1.5
Others (%) 8.0 7.5 8.1 6.1 9.6
Diabetes (%) 29.5 24.1 30.7 0.016 26.2 32.5 <0.001
Registered CV events
(%)
76.0 76.4 75.9 0.6 76.2 75.8 0.8
Calciﬁcation (%) 41.8 26.7 45.1 <0.001 48.2 36.2 <0.001
Continued
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between non-Mediterranean and Mediterranean countries
(Table 3). Slightly less than 20% and 30% of the whole
COSMOS population has been on haemodialysis for <1 and
more than 5 years, respectively (Table 3). The Mediterranean
countries had signiﬁcantly more long-term (>5 years) and
fewer short-term (<1 year) patients on dialysis (Table 3).
The primary aetiology of CKD showed signiﬁcant vari-
ations among the different European regions. This was par-
ticularly evident in Western Europe. Diabetic nephropathy,
hypertension and glomerulonephritis accounted for almost
60% of the causes of CKD (Table 3). Diabetic nephropathy as
aetiology of CKD, and diabetes as a diagnosis in the haemo-
dialysis population were signiﬁcantly more frequent in the
Western and non-Mediterranean countries (P < 0.02). In the
whole COSMOS population, the percentage of CKD diabetic
patients on dialysis at the time of recruitment was close to 30%
(Table 3). The lowest percentage of diabetics (24.1%) was ob-
served in the Eastern countries.
Conventional low- and high-ﬂux dialysis were the most fre-
quently used dialysis techniques (90.4% of patients). Haemo-
diaﬁltration and other techniques were used in 9.6% of
patients; this ﬁgure was slightly higher (11.3%) in the Mediter-
ranean countries (Table 3). The calcium concentration in the
dialysate used in the different facilities ranged from 2.5 to 3.5
mEq/L; the most frequently used concentration was 3.0 mEq/L
(49.5%, Table 3). This ﬁgure was mainly driven by the
Western countries. In the Eastern countries, the percentage of
facilities using 3.5 mEq/L was ∼9% higher than in the Western
countries (Table 3).
The percentage of patients with any kind of cardiovascular
event was uniformly high (76.0%) and the percentage of
patients in whom calciﬁcation was reported was 41.8%
(Table 3). Vascular and valvular calciﬁcations were the most
frequent (34.1 and 14.9%, respectively). Reported calciﬁcations
were higher in Western, and Mediterranean countries.
In 57.7% of the centres, PTH was frequently measured
(every 3 months or more frequently); this was particularly
evident in the Western countries. In the remaining centres,
PTH was investigated either less frequently or not routinely
(Table 4). Serum calcium and phosphorous were measured
monthly or even more frequently in more than 90% of the
centres. This strategy was quite homogeneous across the four
European regions analysed.
Figure 1 shows overall the percentage of patients achieving
the K/DIGO and the K/DOQI targets. Western and Mediterra-
nean countries showed a better control of biochemical par-
ameters (Table 4). Most patients (70.5%) showed serum
phosphorous levels above the normal range (K/DIGO rec-
ommendation).
In those centres reporting the PTH assay used (79.3%),
Elecsys PTH (Roche Diagnostics), Immulite 2000-intact PTH
(DPC) and ELISA-PTH (Schering-Cis Bio) were the most
used (33.3, 18.9 and 13.9%, of the reported assays, respect-
ively) representing 66.1% of the reported assays. The remain-
ing 33.9% correspond to other 11 assays used scattered in 61
centres that they were not included in the corrections or com-
parisons. Serum PTH was higher in patients from centres
using Immulite 2000-intact PTH than in patients from centres
using Elecsys PTH (329.1 ± 358.2 versus 284.0 ± 324.5,
P = 0.006), but no signiﬁcant differences were found between
the ELISA-PTH and Elecsys PTH (316.5 ± 342.2 versus
284.0 ± 324.5, P = 0.08).
In COSMOS, the majority of centres (94.5%) initiated
active vitamin D treatment (calcitriol, alfacalcidol and parical-
citol) with PTH levels between 150 and 499 pg/mL, half of
them between 155 and 299 pg/mL and the other half between
Table 3. Continued
Facilities All
(n = 227)
East
(n = 40)
West
(n = 187)
P-value Medit.
(n = 107)
Non-Medit.
(n = 120)
P-value
Type of haemodialysis technique
Conventional low
ﬂux (%)
52.8 66.5 49.7 <0.001 51.1 54.2 0.001
Conventional high
ﬂux (%)
37.6 26.0 40.2 37.5 37.7
Haemodiaﬁltration
and other (%)
9.6 7.4 10.1 11.3 8.1
Ca conc. in the dialysate (mEq/L)
2.5 (%) 29.8 42.7 26.8 <0.001 19.9 37.2 <0.001
3.0 (%) 49.5 30.1 54.0 57.3 43.6
3.5 (%) 20.7 27.2 19.3 22.8 19.2
Statistical differences between patients from the European regions were adjusted by age and gender. CKD, chronic kidney disease; CV,
cardiovascular; Ca conc., calcium concentration.
aIncludes nephroangiosclerosis.
bInterstitial and obstructive nephropathy.
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Table 4. Facilities: frequency of measurement of biochemical parameters
Facilities All
(n = 227)
East
(n = 40)
West
(n = 187)
P-value Medit.
(n = 107)
Non-Medit.
(n = 120)
P-value
Frequency of PTH measurement
Every 3 months or
less (%)
57.7 40.0 61.5 <0.001 63.6 52.5 0.1
More than every 3
months (%)
39.2 47.5 37.4 35.5 42.5
Non-routinely
(%)
3.1 12.5 1.1 0.9 5.0
Frequency of Ca and P measurement
Every 1 month or
less (%)
92.1 97.5 90.9 0.2 90.7 93.3 0.5
More than every 1
month (%)
7.9 2.5 9.1 9.3 6.7
Patients n = 4500 n = 810 n = 3690 n = 2110 n = 2390
K/DOQI initiative
Ca (mg/dL)
<8.4 (%) 12.7 15.4 12.1 <0.001 12.9 12.5 0.011
8.4–9.5 (%) 57.8 49.5 59.7 59.7 56.0
>9.5 (%) 29.5 35.0 28.3 27.3 31.5
P (mg/dL)
<3.5 (%) 7.2 6.7 7.2 <0.001 9.7 4.9 <0.001
3.5–5.5 (%) 51.5 40.8 53.8 58.3 45.4
>5.5 (%) 41.4 52.5 39.0 32.0 49.7
PTH (pg/mL)
<150 (%) 36.5 42.1 35.4 <0.001 31.6 41.1 <0.001
150–≤300 (%) 29.1 24.9 29.9 30.8 27.5
>300–≤800 (%) 27.0 23.4 27.7 29.4 24.8
>800 (%) 7.4 9.6 7.0 8.2 6.7
K/DIGO initiative
Ca (mg/dL)
Below normal
range (%)
16.5 18.5 16.1 0.001 16.9 16.1 0.8
Within normal
rangea (%)
77.0 72.3 78.0 76.6 77.3
Above normal
range (%)
6.5 9.1 5.9 6.5 6.6
P (mg/dL)
Below normal
range (%)
2.8 2.4 2.9 0.001 4.2 1.5 <0.001
Within normal
rangea (%)
26.7 21.7 27.8 32.5 21.5
Continued
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300 and 499 pg/mL (Table 4). There were differences in the
levels of PTH required to initiate treatment across the different
European regions (Table 4). The higher the level of PTH con-
sidered by each centre to initiate active treatment, the higher
the measured levels of serum PTH found in patients
(Figure 2).
Active vitamin D was used in 48% of patients (Table 5), cal-
citriol and alfacalcidol, in similar percentages, accounted for
93.3% of the active vitamin D use and paricalcitol for 6.7%.
The most frequent route of administration was oral (daily +
intermittent). These two combinations represented 77.9% of
the active vitamin D use, but the oral daily (46.7%) was the
most common form. The intravenous route was much more
commonly used in the Western and Mediterranean countries.
There were differences in the use of calcitriol or alfacalcidol in
the Mediterranean and non-Mediterranean countries. Calci-
triol use was double that of alfacalcidol in Mediterranean
countries and the opposite was seen in non-Mediterranean
countries. Vitamin D as nutritional replacement was used in
30.6% of patients. A total of 6.3% of patients were receiving
calcimimetics.
The majority of COSMOS patients (86.4%) were
receiving phosphate binders, 63.4% received calcium-contain-
ing phosphate binders, the latter increasing to 83.1% in the
Eastern countries. Despite the high percentage of phosphate
binder prescription, 70.5% of patients showed serum phos-
phorous levels above the K/DIGO recommended target
(Table 4).
Table 4. Continued
Facilities All
(n = 227)
East
(n = 40)
West
(n = 187)
P-value Medit.
(n = 107)
Non-Medit.
(n = 120)
P-value
Above normal
range (%)
70.5 75.9 69.4 63.3 77.0
PTH (pg/mL)
<2 times the
upper limita
(%)
31.2 37.0 30.1 <0.001 26.2 35.9 <0.001
2–9 times the
upper limita
(%)
56.1 47.8 57.7 60.8 51.7
>9 times the
upper limita
(%)
12.7 15.2 12.2 13.0 12.3
Patients: percentage of patients distributed according to different ranges of calcium (Ca), phosphorous (P) and PTH. Statistical differences
in patients were adjusted by age and gender.
aNormal range for serum P 3.0–4.5 mg/dL, serum Ca 8.5–10.2 mg/dL and serum PTH 10–65 pg/mL.
F IGURE 1 : Percentage of patients within K/DOQI and K/DIGO
targets for serum calcium, phosphorous and PTH.
F IGURE 2 : Measured serum PTH in patients (patient form) and
serum PTH levels a patient is considered to require active treatment
to lower PTH (centre-speciﬁc form) (mean ± standard error of the
mean). ANOVA test was used to analyse statistical differences.
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Most dialysis facilities considered parathyroidectomy when
PTH was above 750 pg/mL (87.2%). There were differences
between Mediterranean and non-Mediterranean countries, the
latter indicating earlier the surgical procedure (Figure 3A).
The proportion of Mediterranean facilities not performing
parathyroidectomies in the previous year was higher than in
the non-Mediterranean countries (Figure 3B); however,
overall, the percentage of parathyroidectomised patients was
6.6% with no differences across all European regions. Subtotal
and total parathyroidectomy with implants was the preferred
surgical approach (88.5%). Only 17.2% of facilities preferred
the total parathyroidectomy.
DISCUSSION
COSMOS is a prospective study in which haemodialysis
centres and patients were randomly selected from 20 European
countries. The only study with comparable characteristics is
the Dialysis Outcomes and Practice Patterns Study (DOPPS).
However, there are relevant differences between both study
designs; for instance, a sampling proportional to the haemo-
dialysis population of each country was performed in
COSMOS, meanwhile in DOPPS, each European country
aimed to recruit the same sample size with similar number of
centres and patients [20]. Thus, while DOPPS design facilitates
Table 5. Facilities: serum PTH levels required to initiate treatment of secondary
hyperparathyroidism and preferred route and frequency of vitamin D (vit. D) administration
Facilities All
(n = 227)
East
(n = 40)
West
(n = 187)
P-
value
Medit.
(n = 107)
Non-Medit.
(n = 120)
P-
value
Level of PTH to initiate treatment
<150 pg/mL (%) 2.3 5.1 1.7 0.1 2.9 1.7 0.3
150–299 pg/mL (%) 47.5 51.3 46.7 40.8 53.4
300–499 pg/mL (%) 47.0 35.9 49.4 53.4 41.4
>500 pg/mL (%) 3.2 7.7 2.2 2.9 3.4
Frequency/route of active vit. D administration
Intravenous and
intermittent (%)
16.7 5.0 19.3 29.9 5.0 <0.001
Oral and intermittent
(%)
43.6 52.5 41.7 41.1 45.8
Oral and daily (%) 39.6 42.5 39.0 0.1 29.0 49.2
Patients n = 4500 n = 810 n = 3690 n = 2110 n = 2390
Active vit. D 48.0 48.7 47.8 0.7 45.3 50.4 <0.001
Calcitriol (%) 21.2 22.6 20.9 0.4 25.7 17.2 <0.001
Alfacalcidol (%) 23.6 25.6 23.2 0.2 13.9 32.2 <0.001
Paricalcitol 3.2 0.5 3.8 <0.001 5.8 1.0 <0.001
Active vit. D route
Intravenous (%) 22.1 5.8 25.8 <0.001 39.4 8.5 <0.001
Oral intermitent (%) 31.2 23.1 33.0 30.9 31.4
Oral daily (%) 46.7 71.1 41.2 29.7 60.1
Vit. D nutritional replacement (native vitamin D and/or calcidiol)
25 (OH) D (%) 14.2 22.0 12.5 <0.001 13.7 14.7 <0.001
Vit D (%) 14.6 1.2 17.5 13.0 16.0
Both (%) 1.8 2.1 1.8 0.5 3.1
None (%) 69.4 74.7 68.2 72.8 66.3
Phosphate binders (%) 86.4 91.5 85.3 <0.001 86.4 86.4 1.0
Patients: types of vit. D derivatives, route of administration and phosphate binders. Data from the centre-speciﬁc form (facilities) and
patient-speciﬁc form (patients). Statistical differences were adjusted by age and gender.
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making country comparisons, the COSMOS design has a pro-
portional representation of Europe as a whole. Initially, in
order to obtain a representative sample of the European hae-
modialysis population, COSMOS aimed to recruit 5860
patients from 293 dialysis centres. Upon study completion,
77.5 and 76.8% of targeted centres and patients, respectively,
were recruited. Only the UK was underrepresented with
regard to the initial targets; therefore, COSMOS baseline data
can be considered representative of the European haemodialy-
sis population during 2005–07.
Some results observed in COSMOS are consistent with pre-
vious reports. Despite the NECOSAD, from the Netherlands, a
cohort of incident patients (not prevalent as COSMOS), they
reported a similar mean age of the haemodialysis patients to
COSMOS (63 ± 14). The mean age of haemodialysis patients
from non-Mediterranean countries and Western countries
(the groups of countries including the Netherlands) were also
similar in COSMOS (63.4 ± 14.4 and 66.0 ± 13.9, respectively)
(Table 3). The percentages of men were 58.0 and 59.7% in
NECOSAD and COSMOS, respectively [21]. The results from
COSMOS are also comparable with those obtained in the
European countries participating in DOPPS [22]; however, the
COSMOS patients were slightly older (60.4 ± 15.2 versus
64.8 ± 14.2). This small difference might be due to the differ-
ent period of data collection; data from Euro-DOPPS dialysis
units were collected from May 1998 through November 2000,
whereas in COSMOS, the data were collected from February
2005 through July 2007, indicating that the European haemo-
dialysis population is getting older. The mean age found in
COSMOS is also consistent with another recent epidemiologi-
cal study (ARO) carried out in Europe between January 2005
and December 2006, almost the same period in which a great
part of the baseline COSMOS data were collected (63.4 years
in COSMOS and 63.1 years in ARO) [12]. The demographic
characteristics of the COSMOS population are also consistent
with the recent Italian studies FARO and RISCAVID [13–14,
23] and the French Phosphorus and Calcium Observatory
(FPCO) [24, 25] study.
Diabetes is becoming highly prevalent in Europe and else-
where. From 1995 to 1999, the prevalence of type 2 diabetes
increased considerably, particularly in the UK, Germany and
France [26]. The COSMOS data revealed that the most impor-
tant primary cause of CKD in Europe is diabetic nephropathy
(20.4%), higher than that observed in the NECOSAD study [8]
and Euro-DOPPS [22], supporting the remarkable increase in
the prevalence of this disease. The percentage of diabetes as a
diagnosis in the haemodialysis population was also very high
(29.5%) (almost one-third suffering from this disease) being
similar to that found in the FPCO [24] but higher than the
ﬁgures reported in NECOSAD (incident patients older than 50
years) [27] and Euro-DOPPS [28]. The percentage of diabetics
is slightly different in COSMOS and ARO (29.5% in COSMOS
and 25.9 in ARO) studies [12]. However, the countries in-
cluded in ARO are mainly from Eastern Europe and from the
Mediterranean area. The percentage of diabetics in these Euro-
pean regions in COSMOS was more similar to the ARO (24.1
and 26.2 in Eastern and Mediterranean countries, respect-
ively). The differences in the percentage of diabetics among
the different European regions might reﬂect a widespread
group of factors such as genetic, cultural and economic re-
sources.
The proportion of patients with history of cardiovascular
disease was very high in COSMOS (76.0%) and similar to that
found in ARO [12], FARO [23] and other studies [29], but
much higher than that found in NECOSAD [30], in the FPCO
[24] and in a recently published Spanish report [31]. In con-
trast, the reported prevalence of calciﬁcations found in
COSMOS was lower than previous non-observational studies
designed to detect vascular calciﬁcations [32, 33]. As
COSMOS was not speciﬁcally designed to detect or follow vas-
cular calciﬁcations, it is likely that the latter has been underes-
timated in COSMOS.
DOPPS reported in the late 1990s that European haemodia-
lysis patients were treated mainly by low-ﬂux (63.1%) and
high-ﬂux haemodialysis (25.2%) [34]. COSMOS baseline data,
which represent a wide European dialysis scenario, reveal,
almost 6–7 years later, a trend towards an increased use of
F IGURE 3 : Serum PTH levels considered to perform parathyroi-
dectomy (PTX) (A) and number of PTX performed during the pre-
vious 12 months (B) (centre-speciﬁc form). Statistical differences
were assessed by the χ2 test.
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high-ﬂux techniques, especially in Western Europe (40.2% of
patients). KDIGO clinical practice guidelines recommend the
use of a dialysate calcium concentration between 2.5 and 3.0
mEq/L [7]; other authors even recommend lower values [35].
In COSMOS, it was found that a high percentage of patients
(20.7%) was dialysed with a high calcium dialysate concen-
tration (3.5 mEq/L), mainly driven by the Eastern countries
(27.2% of patients).
A great variability among the PTH available assays has
already been described [17, 36]. In some cases, the differences
are so important that a correction is needed; in our study that
was the case of the bio-intact PTH in which the measured
serum values were multiplied by a correcting factor of 1.95
[18, 19]. There were no signiﬁcant differences between the
Elecsys PTH (Roche Diagnostic) and the ELISA-PTH (Scher-
ing-Cis Bio), but signiﬁcant differences were observed between
Elecsys PTH and Immulite 2000-intact PTH (DPC),
suggesting the convenience to correct the latter. Unfortunately,
the correction was not possible due to the fact that COSMOS
did not collect information regarding whether the PTH analy-
sis was measured in serum or plasma, data needed to make the
PTH correction [36].
K/DOQI targets achievement was assessed for compara-
tive purposes. A slightly better control of all bone laboratory
parameters was found in COSMOS compared with the
NECOSAD [37], but the results were similar to most of other
contemporary studies such as RISCAVID [14], FARO [13],
FPCO [25] and ARO [12]. The results were not the same
across the different European regions considered in the
analysis. Eastern countries showed a poorer control of the
main laboratory parameters, particularly serum phosphorous
levels, compared with Western countries. In addition,
patients from Eastern and non-Mediterranean countries
showed a higher percentage of patients with low serum PTH
levels (<150 pg/mL) (Table 4), despite the fact that there
were no important differences in the percentage of patients
treated with active vitamin D metabolites (Table 5). This
result is particularly striking in the Eastern countries,
because these patients tended to be younger and with a lower
proportion of diabetics. Differences in the modality of treat-
ment, such as a higher percentage of patients treated with
phosphate binders (particularly calcium containing phos-
phate binders) in the Eastern countries, may account for
some of these differences.
The distribution of patients within K/DIGO targets was
also investigated. The K/DIGO initiative recommend to main-
tain the CKD5 patients within the normal range for serum
calcium and phosphorous and within two to nine times the
upper limit of the normal range for serum PTH [7]. As the K/
DIGO guidelines referred only to ‘normal ranges or times fold
from normal ranges’, but no speciﬁc serum values are men-
tioned, we decided to use cut-off values for comparison
(Table 4) based on the data of several publications and docu-
ments [17, 38–43] and also based on the more current
decision-making values used in clinical practice. The cut-off
values selected as normal ranges were 3.0–4.5 mg/dL for
serum phosphorous, 8.5–10.2 mg/dL for serum Ca and 10–65
pg/mL for serum PTH.
Using the K/DIGO criteria, we found results that merit
some comments. One striking observation was the high per-
centage of patients that we found above the recommended
serum phosphorous targets (70.5%). The Eastern and non-
Mediterranean countries showed the highest percentages (75.9
and 77%, respectively), but also a poorer control of serum
PTH.
These high ﬁgures stress the difﬁculties in achieving some
guidelines targets, which in some cases, like in serum phos-
phorus, despite the fact that 86.4% of patients were receiving
phosphate binders, only 26.7% achieved the recommended K/
DIGO serum phosphorus values. The knowledge of these
results involve some potential beneﬁts and risks. On the one
hand, they can stimulate a more careful and systematic control
of the phosphate including a more tailored use of phosphate
binders [44, 45], but on the other hand, there is a potential
risk to think that these kind of ‘normal targets’ will never be
achieved, becoming more an ‘academic and ideal but not a
practical, feasible and achievable goal’, a fact which may relax
the willingness and effort to achieve them.
Another interesting ﬁnding is the results observed in serum
PTH. Despite the wider range of ‘normality’ in PTH of the K/
DIGO compared with the K/DOQI targets, only 56.1% of
patients showed PTH levels within the recommended two to
nine times the upper limit of the normal range, despite 48% of
them receiving calcitriol, alfacalcidol or paricalcitol, 30.6%
native vitamin D or calcidiol, 6.3% calcimimetics and 86.4%
phosphate binders. The analysis of the PTH levels out of target
(43.9%) revealed that 71.1% of them showed serum PTH levels
in the ‘low-bone turnover’ range.
The different availability and the cost of the drugs used to
treat secondary hyperparathyroidism and other abnormalities
of the CKD–MBD constellation may have contributed to the
different control in some of the biochemical parameters ob-
served in COSMOS. However, the different strategies and pol-
icies followed by each centre or country may have also played a
role. For example, the centres which planned to initiate treat-
ment with active vitamin D at lower serum PTH levels
achieved in their patients lower serum PTH levels (Figure 2).
In COSMOS, the minority of haemodialysis patients
(30.6%) were receiving some form of native vitamin D, similar
to the FPCO (32.3%) [24]. In contrast, 48% of the patients re-
ceived active vitamin D metabolites, a ﬁgure higher than that
observed in the FPCO [24], but lower than that found in the
FARO [13] and RISCAVID [14]. In agreement with data from
the FPCO [24] and FARO [13], oral administration of active
vitamin D was the predominant route of administration in
COSMOS. The oral use of active vitamin D metabolites was
more frequent in Eastern and non-Mediterranean countries.
A larger proportion of COSMOS patients received phos-
phate binders (86.4%) as it has been described in previous
studies [13, 21, 46]. Given the fact that the use of high doses of
calcium-containing phosphate binders has been associated
with increased coronary artery and aortic calciﬁcation [47–
50], it is important to note that calcium-containing phosphate
binders were the most common phosphate binders prescribed
(63.4%) in the COSMOS population, higher than that found
in the FPCO (57.0%) [25] and in FARO (47%) [13], reaching
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the highest proportions in Eastern and non-Mediterranean
countries (Table 5).
Despite the existing effective therapies for the treatment of
secondary hyperparathyroidism, the proportion of haemodia-
lysis patients parathyroidectomized was still high (6.6%),
similar to the FPCO (7.1%) [24]. However, it is important to
stress that COSMOS and FPCO baseline data reﬂect just the
beginning of the use of new drugs, like calcimimetics and new
vitamin D receptor activators such as paricalcitol, so that the
possible beneﬁts of these new compounds in the management
of secondary hyperparathyroidism cannot be evaluated in this
baseline COSMOS analysis.
There were important differences within the European
regions in the serum cut-off PTH levels used for deciding
when to perform a parathyroidectomy. In the Mediterranean
countries, 63.1% of dialysis centres considered performing a
parathyroidectomy when PTH was higher than 1000 pg/mL,
in contrast to lower cut-off levels found in the non-Mediterra-
nean countries (Figure 3A). As a consequence, the percentage
of dialysis centres performing parathyroidectomies in the pre-
vious 12 months of the inclusion in COSMOS was lower in the
Mediterranean countries (63.6 versus 75.0%, Figure 3B).
Despite the differences observed in the general criteria in de-
ciding when to perform a parathyroidectomy, the percentage
of parathyroidectomized patients was homogeneous across all
regions compared (6.6%).
One important limitation of COSMOS and other observa-
tional studies in which the prescription of drugs is recorded is
that the real intake of them is unknown as it is a matter of ad-
herence and compliance. In CKD 5D, almost all patients are
receiving multiple treatments. Some of the drugs can be per-
ceived to be more important for the patient than others due to
multiple reasons such as better knowledge of the compli-
cations of this speciﬁc problem, mobility advantages, pain
relief, positive effect on well-known heart risk factors, and
several others. All these circumstances may impact the adher-
ence and compliance of drugs used in the control of the CKD–
MBD, which are not prescribed to solve either acute symptoms
or obvious problems for the patient, thus they can be easily
considered less important, reducing or discontinuing their
intake and consequently impacting negatively on the achieve-
ment of CKD–MBD targets. The implementation of edu-
cational programmes designed to explain and clarify the
importance and advantages of keeping the serum biochemical
markers of CKD–MBD under control may help to improve
results in this area [51].
In summary, the COSMOS baseline results show a real
scenario of the European haemodialysis population character-
ized by an elevated age and a high prevalence of diabetes and
cardiovascular disease. The management of secondary hyper-
parathyroidism shows differences across Europe. Patient de-
mographics, medical history, comorbidities, treatment options
and laboratory parameters are still heterogeneous in the differ-
ent European regions analysed. Some of the observed differ-
ences can be attributed to differences in ﬁnancial resources
and health-care models, but others cannot be related to them.
Using the K/DIGO targets for CKD–MBD serum par-
ameters, a great percentage of CKD 5 patients are quite
outside the recommended ranges in the three main serum bio-
chemical parameters analysed, mainly in serum phosphorus.
Recent advances in the pathogenesis of CKD–MBD together
with the progressive use of new safe and active drugs may con-
tribute to a better control of these disorders in renal patients.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.
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